Skip to content

Surgical Removal of Visceral Fat Tissue (Omentectomy) Associated to Bariatric Surgery: Effects on Insulin Sensitivity

Effects of the Surgical Removal of Visceral Fat Tissue (Omentectomy) on Insulin Sensitivity in Grade III Obese Volunteers Subjected to Bariatric Surgery

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00545805
Enrollment
20
Registered
2007-10-17
Start date
2005-10-31
Completion date
2009-06-30
Last updated
2013-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin Resistance, Metabolic Syndrome X, Obesity

Keywords

Insulin resistance, Metabolic syndrome X, Obesity, Intra-Abdominal Fat, Omentum, Bariatric surgery, Glucose Clamp Technique, Intravenous Glucose Tolerance Test, Adiponectin, Cytokines

Brief summary

The intraabdominal fat is associated with insulin resistance, a condition that is in the basis of diabetes, metabolic syndrome and some cardiovascular diseases. It is not clear whether it is the origin of it or a surrogate marker only. We intend to compare the effects of bariatric surgery with versus without omentectomy in morbidly obese people intended to go through bariatric surgery, accessing insulin sensitivity by metabolic tests. If the visceral fat is causative of insulin resistance, its surgical removal (omentectomy) might lead to improvement of insulin action, as seen in animal studies and in one study with morbidly obese human volunteers.

Detailed description

In order to verify a potential additional benefit of omentectomy combined to Roux-en-Y silastic ring gastric bypass, insulin sensitivity will be studied by the gold-standard test, euglycemic-hyperinsulinemic clamp, since early postoperative follow-up (before significant weight variation), compared to a control group of bariatric surgery (same technique) alone. The variables will be analyzed in the post surgical evolution for correlation to metabolic changes: adiposity-related hormones and cytokines; lipid profile and other cardiovascular risk factors; molecular expression of biopsied subcutaneous adipocytes in vitro; anthropometrics; ultrasonography of abdominal subcutaneous and intra-abdominal fat depots and carotid intima-media thickness (preclinical atherosclerosis evaluation).

Interventions

PROCEDURERoux-en-Y Gastric Bypass plus total omentectomy

Roux-en-Y Gastric Bypass plus total omentectomy

PROCEDURERoux-en-Y Gastric Bypass

Roux-en-Y Gastric Bypass without omentectomy

Sponsors

Fundação de Amparo à Pesquisa do Estado de São Paulo
CollaboratorOTHER_GOV
University of Campinas, Brazil
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Age between 21 and 50 years. * Female sex. * BMI between 40 and 50kg/m2. * Metabolic syndrome (NCEP/ATP III criteria).

Exclusion criteria

* Weight variation \>5% within 3 months prior to preoperative tests. * Use of antidiabetic medications within 3 months prior to preoperative tests. * HbA1c \>8%. * Use of systemic corticosteroids for longer than 1 week within 3 months prior to preoperative tests. * Hepatic cirrhosis, renal failure or any clinical condition (other than obesity) recognized as impairing insulin sensitivity. * Present Smoking.

Design outcomes

Primary

MeasureTime frame
Increase of insulin sensitivity as measured by euglycemic-hyperinsulinemic clamp.one month, six months and one year.

Secondary

MeasureTime frame
increase of insulin secretion as measured by intravenous glucose tolerance testone month, six months, one year
regression of carotid intima-media thicknessone month, six months, one year
Improvement of the insulin cell signalling in the subcutaneous adipose tissue.one month, six months
increase of adipocytokines linked to greater insulin sensitivity and decrease of others linked to insulin resistanceone month, six months, one year

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026